U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Ra
Molecular Weight 293.924
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RADIUM RA-223 DICHLORIDE

SMILES

[Cl-].[Cl-].[223Ra++]

InChI

InChIKey=RWRDJVNMSZYMDV-SIUYXFDKSA-L
InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Ra
Molecular Weight 223.0185
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23653243; http://www.ncbi.nlm.nih.gov/pubmed/?term=23977665

Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells.

Originator

Curator's Comment: Xofigo (RADIUM RA-223 DICHLORIDE) was discovered by Algeta ASA, a Norwegian biotech, and in-licensed by Bayer

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XOFIGO

Approved Use

Xofigo is an alpha particle-emitting radioactive thera peutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptoma tic bone metastases and no known visceral metastatic disease

Launch Date

1.36857597E12
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

The dose regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.
Route of Administration: Intravenous
Radium-223 dichloride showed a dose-dependent inhibition of MDA-MB-231(SA) breast cancer cell proliferation at concentrations of 400, 800 and 1600 Bq/mLcompared to the control in a 5-day in vitro proliferation assay
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:25:31 UTC 2023
Edited
by admin
on Fri Dec 15 17:25:31 UTC 2023
Record UNII
RJ00KV3VTG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RADIUM RA-223 DICHLORIDE
DASH   ORANGE BOOK  
Common Name English
Radium Ra 223 dichloride [WHO-DD]
Common Name English
ALPHARADIN
Common Name English
BAY 88-8223
Code English
RADIUM RA223 DICHLORIDE
EMA EPAR  
Common Name English
BAY88-8223
Code English
BAY-88-8223
Code English
RADIUM-223 CHLORIDE [MI]
Common Name English
RADIUM CHLORIDE (223RACL2)
Common Name English
RADIUM-223 DICHLORIDE
Common Name English
RADIUM RA223 DICHLORIDE [EMA EPAR]
Common Name English
RADIUM RA 223 DICHLORIDE [USAN]
Common Name English
XOFIGO
Brand Name English
RADIUM RA-223 DICHLORIDE [ORANGE BOOK]
Common Name English
RADIUM RA 223 DICHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
RADIUM CHLORIDE RA-223
Common Name English
RADIUM-223 CHLORIDE
MI  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129819
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
EMA ASSESSMENT REPORTS XOFIGO (AUTHORIZED: PROSTATIC NEOPLASMS)
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
WHO-VATC QV10XX03
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID80893194
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
DRUG CENTRAL
4800
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
EVMPD
SUB129907
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
LACTMED
Radium Ra 223 Dichloride
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
WIKIPEDIA
RADIUM-223 CHLORIDE
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
FDA UNII
RJ00KV3VTG
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
DAILYMED
RJ00KV3VTG
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
CAS
444811-40-9
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
USAN
ZZ-73
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
RXCUI
1424174
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C62535
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
DRUG BANK
DB08913
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
MERCK INDEX
m9481
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2111187
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
SMS_ID
100000155897
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
CHEBI
74895
Created by admin on Fri Dec 15 17:25:31 UTC 2023 , Edited by admin on Fri Dec 15 17:25:31 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY